The conclusion of these analyses was that letrozole (Femara, Novartis) is the most cost-effective intervention in the first-line setting, whilst being of similar cost-effectiveness to anastrozole (Arimidex, AstraZeneca) in the second-line setting. In addition, preliminary results suggest that ...
Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62 Article CAS PubMed Google Scholar Zagar TM, Kaidar-Person O, Tang X et al (2017)...
Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62 Article CAS PubMed Google Scholar Zagar TM, Kaidar-Person O, Tang X et al (2017)...